Histology-Independent Study of the mTOR Inhibitor, Temsirolimus, in Patients with Advanced Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 26 Aug 2016
At a glance
- Drugs Temsirolimus (Primary)
- Indications Cancer
- Focus Biomarker; Therapeutic Use
- 30 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
- 08 Oct 2009 Planned end date (1 Apr 2016) added as reported by ClinicalTrials.gov.
- 17 Apr 2009 New trial record